key: cord-0308134-sl335cpw
authors: The COVID-19 Host Genetics Initiative,; Ganna, A.
title: Mapping the human genetic architecture of COVID-19: an update
date: 2021-11-11
journal: nan
DOI: 10.1101/2021.11.08.21265944
sha: ff2f4bab6471a0cd7fc77c77ebf7a95e2b743c21
doc_id: 308134
cord_uid: sl335cpw

The Coronavirus Disease 2019 (COVID-19) pandemic continues to pose a major public health threat especially in countries with low vaccination rates. To better understand the biological underpinnings of SARS-CoV-2 infection and COVID-19 severity we formed the COVID19 Host Genetics Initiative. Here we present GWAS meta-analysis of up to 125,584 cases and over 2.5 million controls across 60 studies from 25 countries, adding 10 new genome-wide significant loci to the 13 we previously identified1. Genes in novel loci include SFTPD, MUC5B and ACE2, reveal compelling insights regarding disease susceptibility and severity.

. 38 39 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint classifying loci based on the patterns of association across the two better-powered phenotypes 56

(COVID-19 hospitalization and SARS-CoV-2 reported infection). Intuitively, loci that are 57 associated to susceptibility will also be associated to severity as to develop COVID-19, SARS-58

CoV-2 infection needs to first occur. In contrast, those genetic effects that solely modify the 59 course of illness should be associated to severity to illness and not show any association to 60 reported infection except via preferential ascertainment of hospitalized cases in a cohort 61

(Supplementary Methods). We identified 16 loci that are substantially more likely (> 99% 62 posterior probability) to impact the risk of COVID-19 hospitalization and 7 loci that clearly 63 influence susceptibility to SARS-CoV-2 infection (Supplementary Table 3 ). 64

We observed that several loci had a significant heterogeneous effect across studies (6/23 loci 65 with P-value for heterogeneity < 2.2x10 -3 ; Supplementary Table 2 ). Thanks to an increased 66 diversity in our study population (Supplementary Figure 3) we were able to explore if such 67 heterogeneity was due to effect differences across continental ancestry groups. Only one locus 68

(FOXP4) showed a significantly different effect across ancestries (P-value heterogeneity < 7x10 -69 5 ; Supplementary Table 4 and Supplementary Figure 4) , though even at this locus all 70 ancestry groups showed a positive effect estimate. This confirms that factors related to 71

between-study heterogeneity (e.g., variable definition of COVID-19 severity due to different 72 thresholds for testing, hospitalization, and patient recruitment) rather than differences across 73 ancestries are a more likely explanation for the observed heterogeneity in the effect sizes 74 across studies. 75

For the 23 genome-wide significant loci, we explored candidate causal genes and performed a 77 phenome-wide association study to better understand their potential biological mechanisms 78

(Supplementary Table 2 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint We have substantially expanded the genetic analysis of SARS-CoV-2 infection and COVID-19 121 severity by doubling the sample size, identifying 10 novel loci. We developed a new approach to 122 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint systematically assign the 23 discovered loci to either disease susceptibility (7 loci) or disease 123 severity (16 loci). While distinguishing the two phenotypes is challenging because progression 124

to a severe form of the disease requires susceptibility to infection in the first place, it is now 125 evident that the genetic mechanisms involved in these two aspects of the disease can be 126 differentiated. Among the new loci associated with disease susceptibility, ACE2 represents an 127

expected, yet interesting finding. MUC5B, SFTPD, and SLC22A31 are the three most 128

interesting novel loci associated with COVID-19 severity. Their relationship with lung function 129 and lung diseases is consistent with loci previously associated with disease severity. The SPs 130 secreted by alveolar cells, representing an emerging biological mechanism, maintains healthy 131 lung function and facilitates the clearance of pathogens 12 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint

Detailed description of methods applied.

Supplementary Figure 1 Analytical summary of the COVID-19 HGI meta-analysis. Using the analytical plan set by the COVID-19 HGI, each individual study runs their analyses and uploads the results to the Initiative, who then runs the meta-analysis. There are three main analyses that each study can contribute summary statistics to: critically ill COVID-19, hospitalized COVID-19 and reported SARS-CoV-2 infection. The phenotypic criteria used to define cases are listed in the dark grey boxes, along with the numbers of cases (N) included in the final all ancestries meta-analysis. Controls were defined in the same way across all three analyses: as everybody that is not a case e.g. population controls (light grey box). Sensitivity analyses, not reported in this Figure, also used mild/asymptomatic COVID-19 cases as controls. Sample number (N) of controls differed between the analyses due to the difference in number of studies contributing data to these.

Genome-wide association results for COVID-19 critical illness (Release 6). Results of genome-wide association study of critically ill COVID-19 cases vs population controls (n=9,376 cases and n=1,776,645 controls). Critically ill COVID-19 cases defined as those who required respiratory support in hospital or who were deceased due to the disease.

Projection of contributed samples from participating studies into the same PC space. We asked participating studies to perform PC projection using the 1000 Genomes Project and Human Genome Diversity Project as a reference, with a common set of variants. For each panel (except for the reference), colored points correspond to contributed samples from each cohort, whereas gray points correspond to the 1000 Genomes reference samples. Color represents a genetic population that each cohort specified. Since 23andme, genomicsengland100kgp, and MVP only submitted PCA images, we overlaid their submitted transparent images using the same coordinates, instead of directly plotting them.

Forest plots for highly heterogeneous loci. Forest plots for 6/23 loci that showed a significant heterogeneous effect across studies. For each of the loci, effect sizes and confidence intervals are reported for each contributing study. Studies are grouped by ancestry, with summary effects reported for each ancestry subgroup. The summary effect size across all studies is also reported in the bottom panel for each locus.

LocusZoom plots to visualize the meta-analysis results at the loci passing genome-wide significance. For each genome-wide significant locus in three meta-analyses: meta-analysis of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; critical illness, hospitalization, and reported infection, we showed 1) a Manhattan plot of each locus where a color represents a weighted-average r2 value (see COVID-19 Host Genetics Initiative, 2021) to a lead variant (unadjusted P-values from the two-tailed inverse variance weighted meta-analysis); 2) r2 values to a lead variant across gnomAD v2 populations, i.e., African/African-American (AFR), Latino/Admixed American (AMR), Ashkenazi Jewish (ASJ), East Asian (EAS), Estonian (EST), Finnish (FIN), Non-Finish Europeans (NFE), North-Western Europeans (NWE), and Southern Europeans (SEU); 3) genes at a locus; and 4) genes prioritized by each gene prioritization metric where a size of circles represents a rank in each metric. Note that the COVID-19 lead variants were chosen across all the meta-analyses (Supplementary Table 2 ) and were not necessarily a variant with the most significant P-value from each inverse variance weighted meta-analysis.

Genetic correlations and Mendelian randomization causal estimates between 38 traits and COVID-19 critical illness, hospitalization, and SARS-CoV-2 reported infection. Larger squares correspond to more significant P-values, with genetic correlations or MR causal estimates significantly different from zero at a P < 0.05 shown as a full-sized square. Genetic correlations or causal estimates that are significantly different from zero at a false discovery rate (FDR) of 5% are marked with an asterisk. Two-sided P-values were calculated using LDSC for genetic correlations and Inverse variance weighted analysis for MR.

Supplementary Table 1 . Information regarding studies contributing to the consortium. All independent studies that contributed data to at least one of the three main all-ancestries metaanalyses are listed, with more detailed information where available. The COVID-19 HGI analysis plan can be found on the consortium's website https://www.covid19hg.org. Table 2 . Genome-wide significant results from three COVID-19 phenotype meta-analyses. Loci that reached genome-wide significance (P < 1.67 × 10 -8 ) in at least one of our three inverse-variance weighted meta-analyses of COVID-19 phenotypes (results for each loci listed for all three phenotypes): hospitalization due to COVID-19 (n=25,027 cases and n=2,836,272 controls), and reported SARS-COV-2 infection (n=125,584 cases and n=2,575,347 controls). Associations that did not reach significance threshold of P < 1.67 × 10-8 in the particular analysis are colored in grey. Effect allele frequency is the sample size weighted frequency across studies included in each meta-analysis. P-value is reported for meta-analysis variant association with trait (P-value association). Suggested phenotypic impact of each locus is probabilistically assigned as "Disease severity" or "Infection susceptibility", as described in the Supplementary Methods and Supplementary Table 3 . Between-study heterogeneity Pvalues (from a two-tailed Cochran's Q test) are reported only for the analysis corresponding to the suggested phenotype. Genes in linkage disequilibrium (LD) region: Genes that overlap with a genomic range that contains any variants in LD (r2 > 0.6) with each lead variant. A gene with a minimum distance to gene body is bolded. Genes with coding variants: Genes with a loss-offunction or missense variant in LD with a lead variant (r2 > 0.6). eGenes: Genes with a finemapped cis-eQTL variant (PIP > 0.1) in GTEx and eQTL catalog that is in LD with a lead variant . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint (r2 > 0.6). V2G: Highest gene prioritized by OpenTargetGenetics' V2G score. Table 3 . Probabilistic assignment of variants into disease severity vs infection susceptibility. We report the results of the phenotypic impact assignment for each of the genome-wide significant variants reported in Supplementary Table 2 . Beta, standard error and p-values are reported for a restricted meta-analysis of hospitalized COVID19 cases (n cases = 23,988 cases, n controls = 2,834,885) and reported SARS-Cov-2 infection (n=114,516 cases, n=2,138,237 controls), including only studies that only contributed to both analysis. Posterior probabilities are reported, to belong to either a disease severity (prob_SEV) or infection susceptibility model (prob_SEV). The phenotypic impact of each variant is assigned with a probability cut-ff of 99%. Table 4 . Between-ancestry heterogeneity test for COVID-19 meta-analysis lead variants. We report lead variant summary information for each locus reported in Supplementary Table 2 , with meta-analysis results stratified by genetic ancestry (AFR=African, AMR=Ad-mixed American, EAS= East Asian, EUR=European, MID=Middle Eastern, SAS=South Asian). Meta-analysis P-values reported are unadjusted values from a two-tailed inverse-variance weighted meta-analysis. Between-analysis heterogeneity P-values from a chisquared test of the Cochran's Q measure of the effect sizes. Effect allele frequency is the sample size weighted frequency across studies included in each meta-analysis. Sample sizes and number of studies for each ancestry are reported in the table.

Supplementary Table 5 . eGenes in GTEx v8 or eQTL catalogue. Genes with at least one finemapped cis-eQTL variant (PIP > 0.1) that is in LD with a lead variant (r2 > 0.6) in any tissue of GTEx v8 or eQTL catalogue. The r2 column represents the r2 value between the COVID-19 lead variant and eQTL variant. Table 6 . PheWAS associations for GWAS lead variants in LD (r2>0.6) with COVID-19 index variants. We report phenotype associations for variants which are lead variants of their respective phenotype and in LD (r2>0.6) with COVID-19 associated SNPs. The associations were retrieved from OpenTargetsGenetics, UK Biobank and FinnGen. Table 7 . SNP heritability estimated for three meta-analysis phenotypes. We used LD score regression (LDSC) to estimate SNP heritability from the European-only summary statistics and All ancestries summary statistics, for our three meta-analysis phenotypes. Heritability P-value was calculated from a two-sided z-distribution. All analyses were performed using European panel LD scores. Table 8 . Genetic correlation results between complex traits and COVID phenotypes (EUR only). Two-sided P-values were obtained using LD score regression and adjustments for multiple comparisons were made using FDR. Phenotypes surviving FDR are bolded. Table 9 . Causal association of complex traits on COVID-19 phenotypes (EUR only). Two-sided P-values for the primary analysis were obtained using a fixed-effects inverse weighted analysis, with multiple comparisons adjusted for using FDR. Two-sided P-values for the sensitivity analyses were obtained using weighted median estimator (WME), weighted mode based estimator (WMBE), MR Egger regression and MR-PRESSO outlier corrected estimates.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint Supplementary table 10 A. Direct effects of BMI and type 2 diabetes on risk of SARS-CoV-2 phenotypes using Multivariable Mendelian Randomization. 10B. Test for weak instruments using Sanderson-Windmeijer conditional F-statistics in multivariable MR. Table 11 . Study specific acknowledgements and competing interests.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.08.21265944 doi: medRxiv preprint

Mapping the human genetic architecture of COVID-19. 151

Genetic loci associated with chronic obstructive pulmonary disease 153 overlap with loci for lung function and pulmonary fibrosis

New genetic signals for lung function highlight pathways and chronic 155 obstructive pulmonary disease associations across multiple ancestries

Human Surfactant Protein D Binds Spike Protein and Acts as an Entry 158 Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles

The ABCs of solute carriers: physiological, pathological and 160 therapeutic implications of human membrane transport proteinsIntroduction

Improving the diagnostic yield of exome-sequencing by predicting gene-163 phenotype associations using large-scale gene expression analysis